Commodore Capital LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1831942.
- Reported value$1.68bn
- Positions33
Holdings: 33 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Relay Therapeutics IncRLAY | COM | 75943R102 | 225 | 13.4% | 12,000,000 | Reduced−5,000,000 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 166 | 9.9% | 3,275,000 | Unchanged | |
| Alkermes plc | SHS | G01767105 | 157 | 9.4% | 3,000,000 | Reduced−1,200,000 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 118 | 7.0% | 3,050,000 | Added+161,993 | |
| Amylyx Pharmaceuticals IncAMLX | COM | 03237H101 | 101 | 6.0% | 5,650,000 | Unchanged | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 94.1 | 5.6% | 2,000,000 | Unchanged | |
| Spyre Therapeutics IncSYRE | COM NEW | 00773J202 | 75.2 | 4.5% | 846,786 | Reduced−1,065,594 | |
| Alto Neuroscience IncANRO | COM SHS | 02157Q109 | 71.9 | 4.3% | 2,723,196 | Unchanged | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 70.3 | 4.2% | 2,250,000 | New+2,250,000 | |
| Eyepoint IncEYPT | COM NEW | 30233G209 | 65.8 | 3.9% | 4,600,000 | Added+1,775,000 | |
| Tyra Biosciences IncTYRA | COM | 90240B106 | 59.9 | 3.6% | 1,875,000 | Reduced−600,000 | |
| Damora Therapeutics Inc | COM NEW | 36322Q206 | 50.4 | 3.0% | 1,939,000 | Unchanged | |
| Celldex Therapeutics Inc NewCLDX | COM NEW | 15117B202 | 50.2 | 3.0% | 1,350,000 | Reduced−1,346,616 | |
| Pharvaris N V | COM | N69605108 | 49.3 | 2.9% | 1,425,000 | Reduced−493,970 | |
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 48.7 | 2.9% | 1,500,000 | Unchanged | |
| Assembly Biosciences IncASMB | COM NEW | 045396207 | 38.9 | 2.3% | 1,415,000 | Added+415,000 | |
| Editas Medicine IncEDIT | COM | 28106W103 | 28.8 | 1.7% | 8,889,000 | New+8,889,000 | |
| Kymera Therapeutics IncKYMR | COM | 501575104 | 28.7 | 1.7% | 250,000 | Reduced−500,000 | |
| Perspective Therapeutics IncCATX | COM NEW | 46489V302 | 21.6 | 1.3% | 6,336,782 | Unchanged | |
| Century Therapeutics IncIPSC | COM | 15673T100 | 21.3 | 1.3% | 8,695,652 | Unchanged | |
| Zura Bio Ltd | CLASS A ORD SHS | G9TY5A101 | 19.2 | 1.1% | 3,250,000 | Unchanged | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 18.8 | 1.1% | 1,018,319 | Added+535,319 | |
| Inflarx NV | COM | N44821101 | 16.4 | 1.0% | 7,300,000 | New+7,300,000 | |
| AN2 Therapeutics IncANTX | COM | 037326105 | 14.2 | 0.8% | 2,933,680 | Added+599,967 | |
| Nuvalent Inc | COM | 670703107 | 12.4 | 0.7% | 100,000 | Reduced−733,600 | |
| SAB Biotherapeutics IncSABS | COM NEW | 78397T202 | 11.2 | 0.7% | 2,870,000 | Reduced−1,531,500 | |
| Inhibikase Therapeutics IncIKT | COM NEW | 45719W205 | 11.0 | 0.7% | 5,397,488 | Unchanged | |
| Relmada Therapeutics IncRLMD | COM | 75955J402 | 9.9 | 0.6% | 1,425,000 | Added+791,099 | |
| Pepgen IncPEPG | COM | 713317105 | 8.1 | 0.5% | 4,475,000 | Unchanged | |
| Research Alliance Corp III | ORD SHS CL A | G75226103 | 5.4 | 0.3% | 500,000 | New+500,000 | |
| Helix Acquisition Corp III | USD CL A ORD SHS | G4444S107 | 5.3 | 0.3% | 500,000 | Unchanged | |
| Leonabio IncLONA | COM | 04746L203 | 4.3 | 0.3% | 464,398 | Unchanged | |
| Vistagen Therapeutics IncVTGN | COM | 92840H400 | 0.6 | <0.1% | 2,788,620 | New+2,788,620 |
Sold out: 8 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals IncCRVS | COM | 221015100 | 0.0 | 0.0% | 0 | Sold out−2,258,735 | |
| Erasca IncERAS | COM | 29479A108 | 0.0 | 0.0% | 0 | Sold out−3,175,000 | |
| Karyopharm Therapeutics IncKPTI | COM NEW | 48576U205 | 0.0 | 0.0% | 0 | Sold out−1,950,000 | |
| Nurix Therapeutics IncNRIX | COM | 67080M103 | 0.0 | 0.0% | 0 | Sold out−2,275,000 | |
| Ocular Therapeutix IncOCUL | COM | 67576A100 | 0.0 | 0.0% | 0 | Sold out−2,575,000 | |
| Palisade Bio IncPALI | COM | 696389402 | 0.0 | 0.0% | 0 | Sold out−7,181,062 | |
| Soleno Therapeutics Inc | COM | 834203309 | 0.0 | 0.0% | 0 | Sold out−652,432 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 0.0 | 0.0% | 0 | Sold out−825,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001831942-26-000033 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.